The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.85
Bid: 4.70
Ask: 5.00
Change: 0.00 (0.00%)
Spread: 0.30 (6.383%)
Open: 4.85
High: 4.85
Low: 4.85
Prev. Close: 4.85
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement with Sipcam in North Africa

27 Jul 2021 07:00

RNS Number : 5264G
Eden Research plc
27 July 2021
 

 

27 July 2021

 

 

Eden Research Plc

("Eden" or "Company")

Distribution Agreement for Mevalone in North Africa

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces that it has signed an agreement ("Agreement") with Sipcam Oxon ("Sipcam") which allows Sipcam to market, distribute and sell, on an exclusive basis, Eden's fungicide product, Mevalone®, in four North African countries, where it will be marketed as "Araw®".

 

The Agreement enables Sipcam to distribute Araw for use initially against Botrytis on wine and table grapes, strawberries, tomatoes and cucurbits (which include cucumber, courgette, squash, melon) in Egypt, Morocco, Algeria and Tunisia.

 

North Africa is well recognised for its agricultural output, which is increasing in quantity and quality. All four countries are members of a biocontrol commission established by the International Organisation for Biological Control (IOBC) which promotes sustainable and environmentally friendly means of managing pests and disease and collaborates with the Food and Agriculture Organisation of the United Nations (FAO), the World Health Organisation (WHO), the Commission of the European Union (CEU) and the European Plant Protection Organisation (EPPO).

 

The fungicidal active ingredients in Araw® are exempt from residue limits and have very low pre-harvest intervals, giving growers the ability to apply the product just prior to harvest, providing maximum benefits and flexibility. This is beneficial for main export markets such as the EU where there are clearly defined maximum residue limits (MRLs) and pesticide residue notifications can lead to rejections at the border.

 

Grapes and tomatoes make up two of the major crop types in Egypt. Increasing exports drive market growth and most of Egypt's fruit and vegetables are exported to the EU. In January 2020, Egypt's Parliament approved a new law that regulates organic agriculture and aims to reduce the use of conventional, synthetic pesticides.

In Tunisia, agricultural produce accounts for over 6% of total exports value and, in particular, exports of organic products are growing. Tunisian organic agriculture also has recognised equivalence with the EU.

Approximately 260,000 hectares of fruit and vegetables are grown in Morocco and in 2020 tomato exports to the EU totalled $529.8million. However, in 2018 up to 7.9% of total Moroccan fruit and vegetable samples analysed by the EU-coordinated control programme (EUCP) exceeded MRLs. Across the whole European market, table grapes were one of the products that most regularly exceeded MRLs.

Commercial activities will begin in the four countries following the receipt of regulatory clearance for the marketing and use of Araw. Following the registration of Eden's Cedroz™ in Morocco earlier this year, we anticipate successful registrations in due course.

Sean Smith, Chief Executive Officer of Eden, commented: "Sipcam currently sells Mevalone® under the brands 3logy® in Italy and Araw® in Spain and Portugal. We believe they are an excellent partner for developing the market in North Africa. This agreement builds on earlier, positive developments where the label for Araw® has been significantly expanded to include a range of new crops in Spain. The experience in Spain is directly transferrable to these North African countries due to similarities in climatic conditions and agricultural practices, so we anticipate relatively easy integration of Araw into crop protection programmes once approval is granted. Mevalone is approved as an organic input in the EU and is well-aligned with the direction of regulatory travel in North Africa."

Giovanni Affaba, Managing Director of Sipcam Oxon said:

"Agriculture is a key sector in most of these North Africa's countries, with the average contribution to total gross domestic product (GDP) being around 13%. Farmers must achieve a very high yield under a strict quality management system (known as Integrated Pest Management) to comply with a quality certification chain. As part of this system, Araw represents an extremely powerful tool to control Botrytis infection, as well as other diseases, in a variety of crops. The formulation is plastic and solvent free and is designed with an innovative encapsulation system - Eden's patented Sustaine® technology, which ensures a controlled release of the active ingredients and allows growers to protect their harvest without residues."

 

 

 

For further information contact:

Eden Research plc

www.edenresearch.com

Sean SmithAlex Abrey

01285 359 555

Cenkos Securities plc (Nominated advisor and broker)

Giles Balleny / Camilla Hume/ Mark Connelly (corporate finance)Michael Johnson (sales)

020 7397 8900

Hawthorn Advisors (Financial PR)

Victoria AinsworthJohanna Pemberton

eden@hawthornadvisors.com

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market: 

Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

Cedroz is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services. 

For more information about Eden, please visit: www.edenresearch.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRFFFFIDRIRFIL
Date   Source Headline
15th Sep 20157:00 amRNSHalf Yearly Report
1st Sep 20157:03 amRNSProduct approval in Greece
24th Aug 20157:00 amRNSTerpeneTech Licence Agreement and Investment
25th Jun 20157:00 amRNSActive substances approved for MRL exemption
10th Jun 201512:25 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
27th May 20157:00 amRNSDirector/PDMR Shareholding
26th May 20157:01 amRNSEU Product Authorisation
20th May 201510:07 amRNSPosting of Annual Report & Notice of AGM
20th May 20157:00 amRNSAgreement with Sipcam covering new products
11th May 20157:00 amRNSAppointment of a Director and Share Options
13th Apr 20157:00 amRNSOption agreement with Taminco
30th Mar 20157:00 amRNSFinal Results
18th Feb 201511:08 amRNSDeath of a Director
2nd Feb 20157:00 amRNSGrant of Patent in South Korea
8th Jan 20157:00 amRNSDirectorate Change
19th Dec 20147:00 amRNSProgress on EU zone approval
1st Dec 20147:00 amRNSLicence Agreement with SUMIAGRO
28th Nov 20147:00 amRNSConversion of all outstanding debt
21st Nov 20143:26 pmRNSPlacing to raise £750,000
21st Nov 20147:00 amRNSLicence Agreement with SIPCAM
29th Sep 20147:00 amRNSSuccessful trials in Greece to combat Botrytis
29th Sep 20147:00 amRNSHalf Yearly Report
18th Aug 20147:00 amRNSDirectorate changes & share options
11th Aug 20147:00 amRNSEvaluation agreement for nematicide
1st Jul 20147:00 amRNSNotice of Decision of Patent in South Korea
26th Jun 201412:37 pmRNSAGM Statement
6th Jun 201410:46 amRNSPosting of Annual Report & Notice of AGM
6th Jun 20147:00 amRNSExtension of TerpeneTech licence agreement
30th May 20147:00 amRNSPreliminary Results
15th May 20147:00 amRNSNotice of Allowance for Mexican patent
8th May 20145:12 pmRNSDeath of a Director
24th Apr 20147:00 amRNSNotice of Allowance for Canada patent
22nd Apr 20147:01 amRNSFirst commercial products launched with Eden tech
10th Mar 20147:00 amRNSFurther progress in EU product approval
13th Jan 20147:00 amRNSData Access Licence and Royalty Agreement
19th Nov 201312:54 pmRNSHolding(s) in Company
18th Nov 201311:48 amRNSHolding(s) in Company
9th Oct 20137:00 amRNSNotice of Allowance from ARIPO
24th Sep 20137:00 amRNSHalf Yearly Report
28th Aug 20137:00 amRNSNotice of Allowance
27th Aug 201310:33 amRNSHolding(s) in Company
24th Jun 20131:39 pmRNSResult of AGM
24th Jun 20137:00 amRNSAGM Statement
5th Jun 20137:00 amRNSLicence agreement for head lice treatment
31st May 20135:22 pmRNSPosting of Annual Report & Notice of AGM
31st May 20137:08 amRNSPreliminary Results
20th May 20137:00 amRNSEU approval for active substances
25th Apr 20137:00 amRNSNotice of Allowance from ARIPO
16th Apr 201311:40 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.